Frontier Biotechnologies
Latest round
- Series C
Last raised
- Jan 2017
Total raised
- $43M
Investors
- 3
About Frontier Biotechnologies
Founded in 2002 and based in Nanjing, China, Frontier Biotechnologies Inc. operates as an innovative drug developer that focuses on AIDS antiviral treatment and pain fields. In 2018, Frontier's product - Aibo Weitai was approved for listing. It listed on the Shanghai Stock Exchange in October 2020 and the stock code is 688221.,Ltd. has become the strategic partner of the company in July 2022. The production base located in Nanjing, Sichuan and Shandong, Nanjing's production base covering an area of 65 Mu. Its products include pipeline and Aikening TM. Pipeline includes FB1002, FB2001, FB3001 and FB6001. FB1002 is a novel broad-spectrum HIV neutralizing antibody. FB3001 is a new transdermal patch for musculoskeletal pain. Frontier Biotechnologies develops long acting polypeptide technology platform and new transdermal patch preparation technology platform.
Who invested in Frontier Biotechnologies
3 investors across 2 rounds
See all investors in Frontier Biotechnologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Frontier Biotechnologies
Who invested in Frontier Biotechnologies?
Frontier Biotechnologies has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Frontier Biotechnologies raised?
Frontier Biotechnologies has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Frontier Biotechnologies last raise money?
Frontier Biotechnologies's most recent round on record is a Series C, in Jan 2017.
What does Frontier Biotechnologies do?
Founded in 2002 and based in Nanjing, China, Frontier Biotechnologies Inc.
Where is Frontier Biotechnologies headquartered?
Frontier Biotechnologies is headquartered in Nanjing, China.
Which VCs invest in companies like Frontier Biotechnologies?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Frontier Biotechnologies's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Frontier Biotechnologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.